Table 1

Baseline characteristics

Baseline
Feedback
(n=104)		Control
(n=102)
Female gender, (%)73 (70)74 (73)
Age, years (SD)53.5 (12.1)51.2 (13.6)
BMI, kg/m2 (SD)26.1 (5.9)25.9 (4.8)
Ethnicity, Caucasian (%)90 (87)85 (83)
Disease duration (years, SD)6.3 (7.07)5.7 (5.85)
DAS28-ESR, (SD)4.0 (1.4)3.8 (1.5)
DAS28-ESR, (%)

  • Remission (<2.6)

  • Low (≥2.6 and <3.2)

  • Moderate (≥3.2 and ≤5.1)

  • High (˃5.1)

16 (15.2)
12 (11.4)
42 (40.0)
27 (25.7)		21 (20.6)
8 (7.8)
41 (40.2)
22 (21.6)
HAQ (SD)1.13 (0.7)0.98 (0.6)
Concomitant medications, (%)

  • Methotrexate

  • Prednisolone or triamcinolone

  • Other csDMARD(s)

  • Triamcinolone acetonide injection (intramuscular) (%)

64 (61)
36 (35)
30 (29)
4 (3.8)		56 (55)
41 (40)
39 (38)
3 (2.9)

  • Number of patients and means are presented, unless otherwise stated.

  • BMI, body mass index; csDMARD, conventional disease modifying antirheumatic drug; DAS28, Disease Activity Score for 28 joints; ESR, Erythrocyte sedimentation rate.